BioWorld

Oct. 26, 2005

View Archived Issues

Rigel, Serono Enter $160M Aurora Kinase Inhibitor Deal

A preclinical program focused on Aurora kinase inhibitors brought Rigel Pharmaceuticals Inc. its fifth oncology deal, this one signed with Serono SA and worth up to $160 million. (BioWorld Today) Read More

Marinus' Series A Nets $29M To Build CNS Drug Pipeline

Read More

Flu Vaccines Now Urged For All Americans Going Forward

Read More

Allon Building Pipeline Of Neuroprotective Products

Read More

Other News To Note

Read More

Appointments And Advancements

Read More